title: A dose-escalation study of carboplatin/cyclophosphamide/etoposide along with autologous bone marrow or peripheral blood stem cell rescue.
abstract: Twenty patients have received 21 courses of high-dose cyclophosphamide (6 g/m2 over 4 days), etoposide (1,800 mg/m2 over 3 days), and carboplatin (800 to 1,600 mg/m2 by continuous infusion over 96 hours) and autologous bone marrow or peripheral blood stem cell rescue. The maximum tolerated dose of this regimen included these doses of cyclophosphamide and etoposide with a total of 1,600 mg/m2 carboplatin. Acute renal failure was the dose-limiting toxicity and, at the maximum tolerated dose, was observed in two patients of 14 evaluable courses. Nonhematologic toxicity was otherwise modest, and the overall response rate was 70% in patients with a wide variety of solid hematologic neoplasms.
authors.affiliation: Department of Medicine, University of California San Diego Cancer Center 92103.
authors.forename: T C
authors.initials: TC
authors.lastname: Shea
authors.forename: A M
authors.initials: AM
authors.lastname: Storniolo
authors.forename: J R
authors.initials: JR
authors.lastname: Mason
authors.forename: B
authors.initials: B
authors.lastname: Newton
authors.forename: M
authors.initials: M
authors.lastname: Mullen
authors.forename: R
authors.initials: R
authors.lastname: Taetle
authors.forename: M R
authors.initials: MR
authors.lastname: Green
mesh_terms: D058186:Acute Kidney Injury / Q000139:chemically induced; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016913:Blood Component Transfusion; D016026:Bone Marrow Transplantation; D002177:Candidiasis / Q000209:etiology; D016190:Carboplatin / Q000008:administration & dosage* / Q000009:adverse effects; D017321:Clinical Trials, Phase I as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage* / Q000009:adverse effects; D005047:Etoposide / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D009503:Neutropenia / Q000139:chemically induced; D012074:Remission Induction; D013234:Stem Cells / Q000473:pathology; D015996:Survival Rate; D013921:Thrombocytopenia / Q000139:chemically induced
chemical_list: D005047:Etoposide; D003520:Cyclophosphamide; D016190:Carboplatin